OCUGEN INC. - COMMON

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

20 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

19 Nov 2024 06:02:34 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

08 Nov 2024 05:45:51 By Nasdaq GlobeNewswire

Ocugen Secures $30 Million in Debt Funding

07 Nov 2024 05:30:55 By Nasdaq GlobeNewswire

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

28 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

22 Oct 2024 06:02:15 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

17 Oct 2024 06:30:11 By Nasdaq GlobeNewswire

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

10 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

09 Oct 2024 05:30:32 By Nasdaq GlobeNewswire

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

02 Oct 2024 05:30:15 By Nasdaq GlobeNewswire

Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

24 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

09 Sep 2024 05:30:12 By Nasdaq GlobeNewswire

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

05 Sep 2024 06:00:07 By Nasdaq GlobeNewswire

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 06:30:42 By Nasdaq GlobeNewswire

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

28 Aug 2024 05:30:32 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

26 Aug 2024 06:02:41 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

08 Aug 2024 05:45:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

05 Aug 2024 05:30:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

02 Aug 2024 14:22:33 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

31 Jul 2024 20:15:46 By Nasdaq GlobeNewswire